1. Home
  2. SFL vs SDGR Comparison

SFL vs SDGR Comparison

Compare SFL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SFL Corporation Ltd

SFL

SFL Corporation Ltd

N/A

Current Price

$10.88

Market Cap

1.8B

ML Signal

N/A

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

N/A

Current Price

$31.74

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SFL
SDGR
Founded
2003
1990
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
SFL
SDGR
Price
$10.88
$31.74
Analyst Decision
Buy
Buy
Analyst Count
4
7
Target Price
$13.30
★ $33.57
AVG Volume (30 Days)
1.4M
★ 1.6M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
★ 8.19%
N/A
EPS Growth
N/A
★ 45.14
EPS
★ N/A
N/A
Revenue
N/A
★ $255,869,000.00
Revenue This Year
$14.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 23.29
52 Week Low
$7.52
$10.95
52 Week High
$13.98
$33.78

Technical Indicators

Market Signals
Indicator
SFL
SDGR
Relative Strength Index (RSI) 31.10 60.28
Support Level $10.73 $11.27
Resistance Level $11.30 $32.15
Average True Range (ATR) 0.45 2.50
MACD -0.19 0.59
Stochastic Oscillator 15.37 78.65

Price Performance

Historical Comparison
SFL
SDGR

About SFL SFL Corporation Ltd

SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities. The company operates as a single reportable segment, generating revenue from long-term, fixed-rate charters. Its Additional revenue sources include sales-type lease interest income, voyage charter and pool revenues, and drilling contract revenues.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Share on Social Networks: